gemfibrozil has been researched along with Chemical and Drug Induced Liver Injury in 18 studies
Chemical and Drug Induced Liver Injury: A spectrum of clinical liver diseases ranging from mild biochemical abnormalities to ACUTE LIVER FAILURE, caused by drugs, drug metabolites, herbal and dietary supplements and chemicals from the environment.
| Excerpt | Relevance | Reference |
|---|---|---|
| "An increased risk for adverse events was observed with gemfibrozil relative to fenofibrate, predominantly driven by an increased rate of rhabdomyolysis." | 3.72 | Risk of adverse events with fibrates. ( Alsheikh-Ali, AA; Karas, RH; Kuvin, JT, 2004) |
| "Statin monotherapy is generally well tolerated, with a low frequency of adverse events." | 2.42 | Safety of statins: focus on clinical pharmacokinetics and drug interactions. ( Bellosta, S; Corsini, A; Paoletti, R, 2004) |
| " Clearly, longer acyl glucuronide half-lives were observed for safe drugs compared to drugs that can cause IDT." | 1.42 | Toxicity of Carboxylic Acid-Containing Drugs: The Role of Acyl Migration and CoA Conjugation Investigated. ( Aatsinki, SM; Hokkanen, J; Lassila, T; Mattila, S; Tolonen, A; Turpeinen, M, 2015) |
| " Among the adverse reactions observed with gemfibrozil are alterations in liver function, cholestatic jaundice, and cholelithiasis." | 1.40 | Gemfibrozil disrupts lysophosphatidylcholine and bile acid homeostasis via PPARα and its relevance to hepatotoxicity. ( Brocker, C; Fang, ZZ; Gonzalez, FJ; Krausz, KW; Liu, A; Qu, A, 2014) |
| " We proposed a systematic classification scheme using FDA-approved drug labeling to assess the DILI potential of drugs, which yielded a benchmark dataset with 287 drugs representing a wide range of therapeutic categories and daily dosage amounts." | 1.37 | FDA-approved drug labeling for the study of drug-induced liver injury. ( Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V, 2011) |
| "Gemfibrozil was discontinued and in a few days AST and ALT levels returned to normal." | 1.37 | Gemfibrozil hepatotoxicity: a case report. ( Comellas Alabern, JF; Domínguez Tordera, P; Ronda Rivero, F, 2011) |
| " An understanding of structure-activity relationships (SARs) of chemicals can make a significant contribution to the identification of potential toxic effects early in the drug development process and aid in avoiding such problems." | 1.36 | Developing structure-activity relationships for the prediction of hepatotoxicity. ( Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ, 2010) |
| " We reviewed gemfibrozil- and fenofibrate-associated adverse event reports (AERs) submitted to the US Food and Drug Administration over a 5-year period." | 1.35 | Relative safety of gemfibrozil and fenofibrate in the absence of concomitant cerivastatin use. ( Alsheikh-Ali, AA; Holoshitz, N; Karas, RH, 2008) |
| " So, the toxicogenomics through this technology may be very powerful for understanding the effect of unknown toxic mechanisms in biological system." | 1.32 | Gene expression analysis of peroxisome proliferators- and phenytoin-induced hepatotoxicity using cDNA microarray. ( Hwang, JW; Hwang, SY; Jeon, KS; Jung, JW; Kang, JS; Kang, KS; Kim, YS; Lee, GJ; Lee, WS; Lee, YS; Li, P; Oh, MJ; Park, JE; Park, JS; Song, BS; Um, CH; Yeo, CD; Youn, JP, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (5.56) | 18.2507 |
| 2000's | 6 (33.33) | 29.6817 |
| 2010's | 11 (61.11) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Fourches, D | 1 |
| Barnes, JC | 1 |
| Day, NC | 1 |
| Bradley, P | 1 |
| Reed, JZ | 1 |
| Tropsha, A | 1 |
| Greene, N | 1 |
| Fisk, L | 1 |
| Naven, RT | 1 |
| Note, RR | 1 |
| Patel, ML | 1 |
| Pelletier, DJ | 1 |
| Morgan, RE | 2 |
| Trauner, M | 1 |
| van Staden, CJ | 2 |
| Lee, PH | 1 |
| Ramachandran, B | 1 |
| Eschenberg, M | 1 |
| Afshari, CA | 2 |
| Qualls, CW | 1 |
| Lightfoot-Dunn, R | 1 |
| Hamadeh, HK | 2 |
| Ekins, S | 1 |
| Williams, AJ | 1 |
| Xu, JJ | 1 |
| Chen, M | 2 |
| Vijay, V | 1 |
| Shi, Q | 2 |
| Liu, Z | 2 |
| Fang, H | 2 |
| Tong, W | 3 |
| Ding, D | 1 |
| Kelly, R | 1 |
| Chen, Y | 1 |
| Kalyanaraman, N | 1 |
| Kalanzi, J | 1 |
| Dunn, RT | 1 |
| Suzuki, A | 1 |
| Thakkar, S | 1 |
| Yu, K | 1 |
| Hu, C | 1 |
| Liu, A | 1 |
| Krausz, KW | 1 |
| Fang, ZZ | 1 |
| Brocker, C | 1 |
| Qu, A | 1 |
| Gonzalez, FJ | 1 |
| Lassila, T | 1 |
| Hokkanen, J | 1 |
| Aatsinki, SM | 1 |
| Mattila, S | 1 |
| Turpeinen, M | 1 |
| Tolonen, A | 1 |
| Domínguez Tordera, P | 1 |
| Comellas Alabern, JF | 1 |
| Ronda Rivero, F | 1 |
| Bellosta, S | 1 |
| Paoletti, R | 1 |
| Corsini, A | 1 |
| Alsheikh-Ali, AA | 2 |
| Kuvin, JT | 1 |
| Karas, RH | 2 |
| Jung, JW | 1 |
| Park, JS | 1 |
| Hwang, JW | 1 |
| Kang, KS | 1 |
| Lee, YS | 1 |
| Song, BS | 1 |
| Lee, GJ | 1 |
| Yeo, CD | 1 |
| Kang, JS | 1 |
| Lee, WS | 1 |
| Jeon, KS | 1 |
| Um, CH | 1 |
| Kim, YS | 1 |
| Oh, MJ | 1 |
| Youn, JP | 1 |
| Li, P | 1 |
| Park, JE | 1 |
| Hwang, SY | 1 |
| Grubisić-Cabo, F | 1 |
| Vrdoljak, E | 1 |
| Holoshitz, N | 1 |
| Bustamante Balén, M | 1 |
| Plumé Gimeno, G | 1 |
| Bau González, I | 1 |
| Berenguer Lapuerta, J | 1 |
| de Diego Lorenzo, A | 1 |
| Catalina, V | 1 |
| García Sánchez, A | 1 |
| Escudero, M | 1 |
| Cos, E | 1 |
| Clemente, G | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Liver Injury by Statins in Coronary Heart Disease (CHD) Patients With History of Hepatitis B Virus (HBV) Infection[NCT02808299] | 600 participants (Anticipated) | Observational | 2016-12-31 | Not yet recruiting | |||
| A Multicenter Study Of Nutraceutical Drinks For Cholesterol (Evaluating Effectiveness and Tolerability)[NCT01152073] | 79 participants (Actual) | Interventional | 2009-10-31 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 reviews available for gemfibrozil and Chemical and Drug Induced Liver Injury
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Pr | 2016 |
Safety of statins: focus on clinical pharmacokinetics and drug interactions.
Topics: Binding, Competitive; Biological Availability; Calcium Channel Blockers; Chemical and Drug Induced L | 2004 |
Safety of statins: focus on clinical pharmacokinetics and drug interactions.
Topics: Binding, Competitive; Biological Availability; Calcium Channel Blockers; Chemical and Drug Induced L | 2004 |
Safety of statins: focus on clinical pharmacokinetics and drug interactions.
Topics: Binding, Competitive; Biological Availability; Calcium Channel Blockers; Chemical and Drug Induced L | 2004 |
Safety of statins: focus on clinical pharmacokinetics and drug interactions.
Topics: Binding, Competitive; Biological Availability; Calcium Channel Blockers; Chemical and Drug Induced L | 2004 |
16 other studies available for gemfibrozil and Chemical and Drug Induced Liver Injury
| Article | Year |
|---|---|
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLI | 2010 |
Developing structure-activity relationships for the prediction of hepatotoxicity.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Humans; Structure-Activity Relationship; | 2010 |
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters | 2010 |
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
FDA-approved drug labeling for the study of drug-induced liver injury.
Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Des | 2011 |
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
Topics: Animals; Anti-Infective Agents; Anti-Inflammatory Agents; Chemical and Drug Induced Liver Injury; Da | 2011 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily | 2013 |
Gemfibrozil disrupts lysophosphatidylcholine and bile acid homeostasis via PPARα and its relevance to hepatotoxicity.
Topics: Animals; Bile Acids and Salts; Chemical and Drug Induced Liver Injury; Chromatography, Liquid; Gemfi | 2014 |
Toxicity of Carboxylic Acid-Containing Drugs: The Role of Acyl Migration and CoA Conjugation Investigated.
Topics: Acetates; Acyl Coenzyme A; Acylation; Carboxylic Acids; Chemical and Drug Induced Liver Injury; Chro | 2015 |
Gemfibrozil hepatotoxicity: a case report.
Topics: Chemical and Drug Induced Liver Injury; Female; Gemfibrozil; Humans; Liver Function Tests; Middle Ag | 2011 |
Risk of adverse events with fibrates.
Topics: Aged; Chemical and Drug Induced Liver Injury; Female; Fenofibrate; Gemfibrozil; Humans; Hyperlipidem | 2004 |
Gene expression analysis of peroxisome proliferators- and phenytoin-induced hepatotoxicity using cDNA microarray.
Topics: Animals; Anticonvulsants; Chemical and Drug Induced Liver Injury; Clofibrate; Dose-Response Relation | 2004 |
Drug-induced hepatitis in a patient with malignant melanoma treated with interferon alfa 2b adjuvantly who had been administered gemfibrozil in therapy.
Topics: Antineoplastic Agents; Chemical and Drug Induced Liver Injury; Drug Interactions; Female; Gemfibrozi | 2006 |
Relative safety of gemfibrozil and fenofibrate in the absence of concomitant cerivastatin use.
Topics: Adverse Drug Reaction Reporting Systems; Chemical and Drug Induced Liver Injury; Databases, Factual; | 2008 |
[Acute hepatitis caused by gemfibrozil].
Topics: Aged; Chemical and Drug Induced Liver Injury; Female; Gemfibrozil; Humans; Hypolipidemic Agents | 1998 |
[Cholestatic hepatitis caused by gemfibrozil].
Topics: Aged; Chemical and Drug Induced Liver Injury; Cholestasis, Intrahepatic; Gemfibrozil; Humans; Hypoli | 2001 |